KPV

Not FDA-approved Evidence grade D — animal or in-vitro data only Updated 2026-10-20

This page describes published research and public regulatory records. It is not medical advice. SoluneFit does not sell, supply, or recommend any compound. The SoluneFit app includes a private, on-device tracker for people who want a record of what they and their clinician have already decided — the app neither suggests compounds nor doses.

Also known as: Lys-Pro-Val, alpha-MSH(11-13), α-MSH 11-13, KPV acetate, lysine-proline-valine.

Regulatory status

Not approved and not a component of any FDA-approved drug. FDA's briefing for the 23-24 July 2026 PCAC proposed NOT adding KPV (free base or acetate) to the 503A bulks list, citing poor characterisation, unknown compounding use and no human data [1][2]; PCAC outcome UNVERIFIED: FDA has posted no minutes or vote summary as of 2026-10-20 (non-FDA reports describe a non-binding vote for inclusion, rulemaking pending). FDA's compounding-risk page lists it as nominated then withdrawn and notes no human exposure data [3]. No FDA warning letter naming KPV was found on fda.gov (searched 2026-10-20; the August 2026 peptide-seller letters checked name other products).

What it is

Tripeptide (Lys-Pro-Val), the C-terminal fragment of alpha-melanocyte-stimulating hormone.

A three-amino-acid fragment of alpha-MSH studied in cells and mice for anti-inflammatory effects, especially in the gut and skin. It has never been tested in people.

What the published research shows

Cell studies, mouse colitis and rodent inflammation models, and one in-vitro human cadaver-skin permeation study; FDA found no human studies at all.

Published human studies and reports (these describe trial populations, not SoluneFit claims):

Mouse colitis models (Dalmasso et al. 2008): KPV in drinking water reduced DSS- and TNBS-induced colitis; nanomolar KPV inhibited NF-kB and cytokine release in human intestinal and T-cell lines.
Human cadaver skin, in vitro (Pawar 2017, as summarised by FDA): KPV permeated skin poorly; iontophoresis and microneedle abrasion increased penetration into the epidermis.
Compounding nomination (withdrawn): 0.1 % topical cream/gel for wound healing and inflammatory skin conditions (psoriasis, eczema); no other dose given.

Mechanism, as reported

Not established. In cell and mouse work it enters cells through the PepT1 transporter and dampens NF-kB inflammatory signalling; it does not appear to act on melanocortin receptors.

Practical record

Studied routes: topical, oral.
Typical supply: No approved product. Marketed online as injectable, oral, topical and nasal-spray products, sometimes combined with BPC-157 or TB-500 (FDA).
Reconstitution: Free base water solubility about 0.7 mg/mL (FDA); no published in-use stability.
Storage: Free base stable up to 3 years at -20 °C; acetate at 2-8 °C (supplier data cited by FDA).

Safety signals on record

Reported adverse events: Unknown: no human data and no adverse-event or food-complaint reports in FDA databases.
Contraindications: None established (no label).
Interactions: None documented.
Notes: No toxicology studies of any kind. Half-life and bioavailability have never been measured. FDA raises immunogenicity and aggregation concerns for injected peptide products.

Sources

General wellness education, not medical advice. Unapproved compounds have no established dosing, purity standard, or safety profile.

← All compounds